Browse studies

Find your next paid study

157 recruiting studies matching your filters

An Open-Label, International, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Intravesical T3011 Injection in Participants With BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) or BCG-Exposed, Chemotherapy-Unresponsive Intermediate /High-Risk NMIBC

This is a Phase II clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMIBC or …

Nonmuscle-invasive Bladder Cancer

Estimated

~$10 – $8,750

ImmVira Pharma Co. LtdNCT06971614

Phase 3

The Phase III Adaptive Radiation and Chemotherapy for Muscle Invasive Bladder Cancer Trial (ARCHER)

This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypo…

Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8

Estimated

~$10 – $7,500

NRG OncologyNCT07097142

Phase 1

A Phase I Trial of Cancer-targeting Micelles for Non-myoinvasive Bladder Cancer

This clinical trial is to determine the safety and effectiveness of an investigational bladder cancer drug named "PLZ4-coated paclitaxel-loaded nanoscale micel…

Non-muscle-invasive Bladder Cancer

Estimated

~$10 – $5,625

VA Office of Research and DevelopmentNCT05519241

Phase 1

Phase I/II Study Evaluating the Safety and Tolerability of Locally Administered Anti-CD40 Agonist Antibody (2141-V11) in Subjects With Bladder Cancer

The purpose of this study is to test the safety of the study drug 2141-V11 in people whose NMIBC did not respond to standard treatment, and who will not have t…

Non-muscle Invasive Bladder Cancer

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT05126472

Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial

This study investigates the feasibility of the Labcorp Plasma Detect, which is an assay (test) that looks for circulating tumor DNA (ctDNA) in patients who hav…

Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8

Estimated

~$10 – $1,125

OHSU Knight Cancer InstituteNCT07726602

Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)

The SCORE-NMIBC study is a prospective, multi-center, study designed to collect data and biological samples from participants diagnosed with non-muscle Invasiv…

Non-Muscle Invasive Bladder CancerNMIBCHigh-risk Non-Muscle Invasive Bladder Cancer

Estimated

~$10 – $1,050

Natera, Inc.NCT07763197

Phase 2

Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC)

This study is a two-arm phase II randomized trial investigating patients with luminal subtype muscle-invasive bladder cancer (MIBC) receiving neoadjuvant thera…

Bladder Cancer

Estimated

~$10 – $6,250

Rutgers, The State University of New JerseyNCT07762586

Phase 1

A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors

The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants wi…

Advanced Solid TumorAdvanced CancerMetastatic Cancer+19 more

Estimated

~$10 – $7,500

MacroGenicsNCT06242470

A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies

Background: Tumors in the genitourinary tracts can occur in the kidney, bladder, prostate, and testicles and can have common and rare histologies. Some cancer…

Urothelial CancerBladder CancerGenitourinary Cancer+2 more

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT04923178

Phase 1

A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment

This study will evaluate the safety and efficacy of intravesical administration of detalimogene (EG-70) in the bladder and its effect on bladder tumors in pati…

Superficial Bladder CancerNon-muscle Invasive Bladder Cancer With Carcinoma in SituNon-muscle Invasive Bladder Cancer

Estimated

~$10 – $8,750

enGene, Inc.NCT04752722

Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy

This study collects and studies tissue and blood samples from patients with prostate or bladder/urothelial cancer that has recurred (come back) at or near the …

Localized Renal Pelvis and Ureter Urothelial CarcinomaMalignant Solid NeoplasmMetastatic Malignant Neoplasm in the Bone+8 more

Estimated

~$10 – $750

University of WashingtonNCT01050504

Phase 1

A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors

This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid …

Colorectal CancerPancreatic CancerMelanoma+13 more

Estimated

~$10 – $8,750

ViroMissile, Inc.NCT06910657